Dallas, TX -- (SBWIRE) --06/03/2011 -- The Australian opioid market grew from $63m in 2005 to $137m in 2009. Its growth will slow considerably and the market will be worth $182m in 2019. As many new drugs to come on the market will be reformulations, Datamonitor assumes that these will be priced at a similar level as currently available brands in order to receive reimbursement. This means that the value of the market will stabilize.
Scope
*Forecast to 2019 for marketed and late-stage pipeline opioid products in Australia.
*Assessment of Australia-specific drivers and resistors likely to impact the market.
*Future market outlook for individual products taking into account key market events, in particular patent expiry and competitor launch dates.
*Case studies examining the commercial potential of anti-abuse compounds and those in development for breakthrough cancer pain.
Highlights
The controlled-release class was the highest-selling class in 2009 with sales of $115m. The fast growth of this class in recent years, particularly between 2006 and 2008, can be almost completely attributed to the uptake of two transdermal patches and the oral drug OxyContin (oxycodone; Mundipharma).
As both OxyContin (oxycodone; Mundipharma) and Durogesic (fentanyl; Janssen-Cilag) will have to battle with the entry of generics and competing products in the oral controlled-release market, Norspan (buprenorphine; Mundipharma) will become the highest-selling drug in the Australian opioid market by 2019 with sales of $34m.
While peak sales of Actiq (fentanyl; Sigma Pharmaceuticals) were over $600m in the US, 2009 sales in Australia only reached $1m. Actiq’s limited listing on the Palliative Care Schedule does not only greatly limit its patient population, it also makes it more cumbersome for physicians to apply for authorizations and repeat prescriptions.
Reasons to Purchase
*Identify key opportunities and threats that will impact the Australian opioid market as a whole and key brands and pipeline products in particular.
*Quantify the future size and scope of the Australian opioid market and predict the performance of its key compounds.
*Understand critical success factors in growing and defending opioid brand franchises from new entrants and generics.
Related Reports:
Opioids Market to 2017 – Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market
Pipeline and Commercial Insight: Moderate to Severe Chronic Nociceptive Pain – Anti-abuse opioids set to prosper
Opioids in Australia Market Forecast
Risk Evaluation and Mitigation Strategy (REMS) – Opioids, Erythropoesis-Stimulating Agents and Cancer Therapeutics are the Most Important Classes That Require REMS
Commercial Insight: Opioids in Australia
Buy Now: Opioids in Australia Market
http://www.reportsnreports.com/reports/24137-commercial-insight-opioids-in-australia.html
Browse all Research Reports On : Opiodis Market
http://www.reportsnreports.com/tags/opioids-market-research.html
About Us
ReportsnReports is comprising of an online library of 75,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts of almost all well-known publishers of such reports across the globe. We, as a third party reseller of market research reports employ number of marketing tools such as press releases, email-marketing and effective search engine optimization technique to drive revenues for our clients.
We also provide 24/7 online and offline support to our customers.
Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: +1-888-989-8004
E-mail: sales@reportsnreports.com
http://www.reportsnreports.com